Skip to content
Aperlena
Free alerts

TED - Tenders Electronic Daily (Publications Office of the EU) verified 7 hours ago Contract notice

Germany - Health services - Central Laboratory Services for Clinical Trial

Open Germany Health & social work

Buyer BiconY Therapeutics GmbH

29 days left

Key facts

Closes
11:00 (UTC+1)
Procedure
Open procedure
  1. Published
  2. Today
  3. Deadline open for 30 days
  4. Awarded pending

Bidding window

29 days from publication to deadline

Usual length

Notices of this kind (Germany, open procedure, above the EU threshold) give a median of 31 days, half of them between 28 and 34 days, based on 83,869 notices of the last two years.

View the official notice Watch this tender
Add to calendar

If the deadline moves or the notice is corrected, we email you. Log in

Summary

Machine-generated summary

SPRIND GmbH, the German Federal Agency for Disruptive Innovation, acts through its subsidiary BiconY Therapeutics GmbH, which is developing a bispecific antibody combination for treating solid tumours. The combination pairs bispecific CD3 antibodies with bispecific CD28 co-stimulators to improve T cell recruitment and the immune response against tumour cells. To demonstrate proof of concept, two phase I/IIa clinical trials are planned. BiconY is procuring a service provider to act as central laboratory for these trials, covering collection logistics, processing, analysis, management, distribution and long-term storage of biological specimens from trial participants, including analysis of cytokines in serum and isolation of peripheral blood mononuclear cells (PBMC).

Description

The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to create new disruptive innovations from Germany. That means products, services and systems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination consists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly improve the specificity, sustainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the conduct of the planned phase I/IIa clinical trials, comprehensive central laboratory services are required for the collection logistics, processing, analysis, management, distribution and long-term storage of the biological specimens obtained from the trial participants. This includes in particular the analysis of cytokines in serum and the isolation of peripheral blood mononuclear cells (PBMC). Therefore, BiconY is looking for a service provider to act as central laboratory for these clinical trials. Please refer to the tender documents for further details. The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to create new disruptive innovations from Germany. That means products, services and systems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of con-cept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the conduct of the planned phase I/IIa clinical trials, comprehensive central laboratory services are required for the collection logistics, processing, analysis, management, distri-bution and long-term storage of the biological specimens obtained from the trial participants. This includes in particular the analysis of cytokines in serum and the isolation of peripheral blood mononuclear cells (PBMC). Therefore, BiconY is looking for a service provider to act as central laboratory for these clinical trials. Please refer to the tender documents for further details.

Bid or no-bid?

Six questions before you commit a team. Under each one, what the register holds on it. The answers are yours.

  1. In your favour:

    Do we meet every eligibility criterion?

    Open procedure: any interested supplier may submit a bid.

    Above the EU threshold: open to companies from any EU country.

  2. Your call:

    Can we deliver this with the team we have?

    The register holds nothing on this. The official documents will.

  3. Your call:

    Do we have two comparable references?

    Comparable work is in Health & social work.

  4. In your favour:

    Is the deadline realistic for a proper offer?

    29 days left, 22 of them working days.

  5. Your call:

    Is there a margin at the likely winning price?

    In this country this kind of contract is usually awarded for between €321,550 and €2.7M.

  6. Your call:

    Do we know this buyer?

    The register holds nothing on this. The official documents will.

Can I bid?

  • Open procedure: any interested supplier may submit a bid. Above the EU threshold: open to companies from any EU country.
  • Certificates from another EU country? Check the equivalents on eCertis

Official source

Source: TED - Tenders Electronic Daily (Publications Office of the EU)

Always verify details on the official notice.

Report an error in this notice

Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 7 hours ago

View the official notice

What this market pays

The buyer has too few awards of its own in this sector, so this is the range of the last 257 awards for Health & social work in Germany.

Median award
€880,000
Middle half of past awards
€321,550 to €2.7M

TED - Tenders Electronic Daily (Publications Office of the EU) publishes no value for this notice, so it has no mark on the scale. The official documents may state one.

Award values as published by the official sources. Use them as a guide, not a rule: scope, lots and duration differ between contracts.

The buyer

Full buyer profile

BiconY Therapeutics GmbH

Germany

This buyer has no award history in this sector yet. Usual winners, Health & social work - Germany

Company Wins Total awarded Last win
AMD TÜV Arbeitsmedizinische Dienste GmbH 10 €3.2M Jun 2026
BG prevent GmbH 7 €1.0M Sep 2026
European Homecare GmbH 6 €16.5M May 2026
Malteser Werke gGmbH 6 €2.7M Sep 2026
PIMA Health & Safety GmbH 6 €136,800 Aug 2026

Based on 666 awards with a linked company profile over the last 2 years.

Market context

TED - Tenders Electronic Daily (Publications Office of the EU) publishes no value for this notice, so it cannot be placed among the open notices of its sector. The official documents may state one.

open now in Health & social work
2,342
median open notice
€484,180

Who wins in this market

Many suppliers

Germany · Health & social work

different companies won awards here
523
of the awards went to the three most frequent winners
3%
buyers awarded contracts here
386

Based on 666 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners.

Competition

tenders per lot on average (open and restricted procedures)
3.6
of those lots received a single tender
22%
of the awards went to companies based in another country
1%
of the tenders came from another country
2%

As the official award notices state them, over the last 3 years. Tenders per lot count open and restricted procedures only: in a negotiated procedure or a direct award a single tender is the procedure itself. The country is the one the notice gives for the winner.

Similar tenders

Open now

Awarded before

Never miss a tender like this

682 new notices in Health & social work in Germany in the last 7 days. Get an email when new ones appear. Free.

Set up my alert

29 days left

Open notice

Keyboard shortcuts

Read a list without reaching for the mouse. The shortcuts stay quiet while you type in a field.

j
Next result
k
Previous result
Enter
Open the result
n
Next page
p
Previous page
c
Compare this result
s
Shortlist this result
o
Open the result in a new tab
x
Set this result aside
/
Search from any page
Ctrl K
Search from any page
?
Show these shortcuts
Esc
Close

Start from a question

Browse by sector

Index

Close
Log in

Language